Published in Arthritis Rheum on July 01, 1991
Cartilage and bone metabolism in rheumatoid arthritis. Differences between rapid and slow progression of disease identified by serum markers of cartilage metabolism. J Clin Invest (1995) 1.77
Immunochemical markers of joint inflammation, skeletal damage and repair: where are we now? Ann Rheum Dis (1994) 1.02
Radiographic severity of rheumatoid arthritis in African Americans: results from a multicenter observational study. Arthritis Care Res (Hoboken) (2010) 0.98
CD44 in rheumatoid arthritis. Arthritis Res Ther (2003) 0.95
Serum hyaluronate level for predicting subclinical liver dysfunction after hepatectomy. World J Surg (2004) 0.88
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study. Arthritis Res Ther (2010) 0.87
Evaluation of serum chondroitin sulfate and hyaluronan: biomarkers for osteoarthritis in canine hip dysplasia. J Vet Sci (2008) 0.83
HA/GSA-Rmax ratio as a predictor of postoperative liver failure. World J Surg (2008) 0.82
Metabolomics in psoriatic disease: pilot study reveals metabolite differences in psoriasis and psoriatic arthritis. F1000Res (2014) 0.80
The effect of doxycycline on canine hip osteoarthritis: design of a 6-months clinical trial. J Vet Sci (2009) 0.79
Serum hyaluronic acid levels in patients with ankylosing spondylitis. Clin Rheumatol (2007) 0.76
Efficacy of radiosynoviorthesis and its impact on chosen inflammatory markers. Rheumatol Int (2011) 0.75
Screening Mucopolysaccharidosis Type IX in Patients with Juvenile Idiopathic Arthritis. JIMD Rep (2015) 0.75
Serum hyaluronic acid levels do not explain morning stiffness in patients with fibromyalgia. Clin Rheumatol (2010) 0.75
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet (1999) 4.98
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2011) 4.78
ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis (2005) 4.31
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis (2009) 3.32
Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp Cell Res (1986) 2.74
Intermediate filaments anchor the nuclei in nuclear monolayers of cultured human fibroblasts. Nature (1978) 2.28
Expression of intermediate filaments in cultured cells. J Cell Sci (1981) 2.25
New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis (2009) 2.22
Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicenter, double-blind, placebo-controlled study. Arthritis Rheum (1995) 2.16
Monoclonal antibodies to a nuclear protein (PCNA/cyclin) associated with DNA replication. Exp Cell Res (1987) 2.13
Double-blind, placebo-controlled study of three-month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis Rheum (1991) 2.10
Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with early rheumatoid arthritis treated with "sawtooth" strategy. Ann Rheum Dis (1998) 2.09
Cardiovascular diseases in patients with rheumatoid arthritis. Scand J Rheumatol (2012) 2.03
Isolated congenital heart block. Long-term outcome of mothers and characterization of the immune response to SS-A/Ro and to SS-B/La. Arthritis Rheum (1993) 1.96
Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis (1992) 1.86
Human smooth muscle autoantibodies reacting with intermediate (100 A) filaments. Nature (1977) 1.82
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis (2004) 1.76
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Ann Rheum Dis (2004) 1.58
Uveitis in young adults with juvenile idiopathic arthritis: a clinical evaluation of 123 patients. Ann Rheum Dis (2005) 1.54
Increased level of YKL-40 in sera from patients with early rheumatoid arthritis: a new marker for disease activity. Rheumatol Int (2001) 1.53
Sonographic analysis of enthesopathy in the lower extremities of patients with spondylarthropathy. Clin Exp Rheumatol (1994) 1.52
Autoantibodies in infectious mononucleosis have specificity for the glycine-alanine repeating region of the Epstein-Barr virus nuclear antigen. J Exp Med (1987) 1.50
Antikeratin antibody and antiperinuclear factor as markers for subclinical rheumatoid disease process. J Rheumatol (1993) 1.46
Autoantibody to "intermediate filament" in infectious mononucleosis. Clin Immunol Immunopathol (1979) 1.45
Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis (1999) 1.44
The detection of human antibodies against cytoskeletal components. J Immunol Methods (1984) 1.43
Juvenile chronic arthritis in adult life: a study of long-term outcome in patients with juvenile chronic arthritis or adult rheumatoid arthritis. Clin Rheumatol (1999) 1.43
Antibodies to cytoplasmic intermediate filaments in rheumatic diseases. J Rheumatol (1983) 1.41
Campylobacter-triggered reactive arthritis: a population-based study. Rheumatology (Oxford) (2002) 1.38
Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet (1993) 1.34
Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis (2002) 1.32
Glial fibrillary acidic protein and intermediate filaments in human glioma cells. Acta Neuropathol (1979) 1.29
A solid phase enzyme-linked immunosurbent assay (ELISA) for the demonstration of antibodies against denatured, single-stranded DNA in patient sera. Scand J Immunol (1978) 1.29
Characterization of the DNA-synthesizing cells in rheumatoid synovial tissue. Scand J Rheumatol (1978) 1.22
Antibodies against cyclic citrullinated peptide (CCP) and levels of cartilage oligomeric matrix protein (COMP) in very early arthritis: relation to diagnosis and disease activity. Scand J Rheumatol (2004) 1.21
The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol (2011) 1.19
Reactive arthritis following an outbreak of Salmonella infection in Finland. Br J Rheumatol (1994) 1.19
Finnish case-control and family studies support PTPN22 R620W polymorphism as a risk factor in rheumatoid arthritis, but suggest only minimal or no effect in juvenile idiopathic arthritis. Genes Immun (2005) 1.19
Reactive arthritis. Clin Rheum Dis (1985) 1.18
Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial. Arthritis Rheum (1988) 1.18
Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum (1996) 1.17
Purification of filaggrin from human epidermis and measurement of antifilaggrin autoantibodies in sera from patients with rheumatoid arthritis by an enzyme-linked immunosorbent assay. Int Arch Allergy Immunol (1998) 1.17
Clinical, radiographic and MRI findings of the temporomandibular joint in patients with different rheumatic diseases. Int J Oral Maxillofac Surg (2006) 1.17
Production of tumour necrosis factor and interleukin 1 by monocytes of patients with previous Yersinia arthritis. Clin Exp Immunol (1988) 1.16
Mortality in patients with rheumatoid arthritis treated actively from the time of diagnosis. Ann Rheum Dis (2002) 1.14
Marker antibodies of rheumatoid arthritis: diagnostic and pathogenetic implications. Semin Arthritis Rheum (1994) 1.14
Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction. Microb Pathog (1990) 1.13
Proliferating cell nuclear antigen (PCNA)/cyclin in activated human T lymphocytes. J Immunol (1987) 1.11
Antifilaggrin antibodies in recent-onset arthritis. Scand J Rheumatol (1999) 1.11
Characterization of human smooth muscle autoantibodies reacting with cytoplasmic intermediate filaments. Clin Immunol Immunopathol (1978) 1.10
Combination drug therapy retards the development of rheumatoid atlantoaxial subluxations. Arthritis Rheum (2000) 1.09
Smooth muscle antibodies of actin and "non-actin" specificity. Clin Immunol Immunopathol (1978) 1.09
Favourable social functioning and health related quality of life of patients with JIA in early adulthood. Ann Rheum Dis (2005) 1.09
Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis (2009) 1.09
Progression of cervical spine changes in patients with early rheumatoid arthritis. J Rheumatol (1997) 1.08
Chlamydia pneumoniae as a triggering infection in reactive arthritis. Rheumatology (Oxford) (1999) 1.08
Reactive arthritis attributable to Shigella infection: a clinical and epidemiological nationwide study. Ann Rheum Dis (2004) 1.07
Antibodies to retroviral proteins in autoimmune connective tissue disease. Relation to clinical manifestations and ribonucleoprotein autoantibodies. Arthritis Rheum (1992) 1.07
Association of autoantibodies to filaggrin with an active disease in early rheumatoid arthritis. Ann Rheum Dis (2001) 1.07
Occurrence of different ensuing triggering infections preceding reactive arthritis: a follow up study. Br Med J (Clin Res Ed) (1988) 1.06
[Antibiotic treatment in rheumatoid arthritis?]. Duodecim (1995) 1.06
Faecal microbial flora and disease activity in rheumatoid arthritis during a vegan diet. Br J Rheumatol (1997) 1.06
Cell-mediated immune response in the diseased joints in patients with reactive arthritis. Scand J Immunol (1986) 1.06
Prevalence and mortality rates of systemic lupus erythematosus and causes of death in SLE patients in Finland. Scand J Rheumatol (1985) 1.04
Profiles of antinuclear antibodies in chronic active hepatitis, primary biliary cirrhosis and alcoholic liver disease. Liver (1984) 1.03
Salmonella-specific antibodies in reactive arthritis. J Infect Dis (1991) 0.99
Fetal outcome in women with primary Sjögren's syndrome. A retrospective case-control study. Clin Exp Rheumatol (1995) 0.98
Type I collagen degradation product in serum of patients with early rheumatoid arthritis: relationship to disease activity and radiological progression in a 3-year follow-up. Br J Rheumatol (1994) 0.98
Treatment strategy, disease activity, and outcome in four cohorts of patients with early rheumatoid arthritis. Ann Rheum Dis (2001) 0.98
Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol (2010) 0.98
Effectiveness of different cryotherapies on pain and disease activity in active rheumatoid arthritis. A randomised single blinded controlled trial. Clin Exp Rheumatol (2006) 0.98
Rheumatoid arthritis as a cause of cardiac compression. Favourable long-term outcome of pericardiectomy. Clin Rheumatol (1993) 0.97
Monetary value of lost productivity over a five year follow up in early rheumatoid arthritis estimated on the basis of official register data on patients' sickness absence and gross income: experience from the FIN-RACo trial. Ann Rheum Dis (2005) 0.97
Prospect for an additional laboratory criterion for rheumatoid arthritis. Scand J Rheumatol (1993) 0.97
Reactive arthritis following an outbreak of Salmonella typhimurium phage type 193 infection. Ann Rheum Dis (2002) 0.97
Predictors of productivity loss in early rheumatoid arthritis: a 5 year follow up study. Ann Rheum Dis (2005) 0.96
Serum immunoglobulins and the risk of rheumatoid arthritis. Ann Rheum Dis (1997) 0.95
Selective endothelial binding of interleukin-2-dependent human T-cell lines derived from different tissues. Proc Natl Acad Sci U S A (1992) 0.95
Cytoskeleton antibodies in chronic active hepatitis, primary biliary cirrhosis, and alcoholic liver disease. Hepatology (1983) 0.94
Salmonella-triggered reactive arthritis: use of polymerase chain reaction, immunocytochemical staining, and gas chromatography-mass spectrometry in the detection of bacterial components from synovial fluid. Arthritis Rheum (1999) 0.94
Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. Ann Rheum Dis (2004) 0.94
Reproductive health in women with systemic lupus erythematosus compared to population controls. Scand J Rheumatol (2009) 0.94
Chlamydial antibodies in patients with previous acute anterior uveitis. Invest Ophthalmol Vis Sci (2001) 0.93
Three cases of cardiac complications associated with Campylobacter jejuni infection and review of the literature. Eur J Clin Microbiol Infect Dis (2005) 0.92
Cellular fibronectin in rheumatoid synovium and synovial fluid: a possible factor contributing to lymphocytic infiltration. Scand J Immunol (1990) 0.92
Persistence of enthesopathic changes in patients with spondylarthropathy during a 6-month follow-up. Clin Exp Rheumatol (1996) 0.92
Wegener's granulomatosis in Finland in 1981-2000: clinical presentation and diagnostic delay. Scand J Rheumatol (2008) 0.91
Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol (2010) 0.91